Public Company Edition: Blackstone Life Sciences Yield will finance approved products, while the firm’s prior fund supports late-stage programs. Also, Coeptis will merge with a SPAC, Bausch + Lomb secured post-IPO debt, and BioXcel revealed a $260m financing and new subsidiary.

Public Company Edition: An IPO and three big follow-on offerings hit the market but other public companies revealed plans to cut costs or reprioritize their R&D pipelines, signaling that uncertainty remains. 

The firm plans to submit to the US FDA in the third quarter and with the European Medicines Agency in the fourth quarter based on positive Phase III study results.

Vancouver biotech is building a pipeline of candidates for rare, severe chronic kidney disease. It has an oral drug in Phase III and an antibody candidate in mid-stage development for IGA nephropathy.